Mitratapide
Clinical data | |
---|---|
Trade names | Yarvitan |
Routes of administration | By mouth (0.5% solution) |
ATCvet code | QA08AB90 (WHO) |
Pharmacokinetic data | |
Bioavailability | 55–69% |
Protein binding | >99.9%[1] |
Metabolism | Extensive liver (sulfoxidation); first pass effect |
Biological half-life | 6.3 hours (mitratapide), up to 44.7 hours (metabolites) |
Excretion | Feces (80–90%)[2] |
Identifiers | |
| |
Synonyms | Mitratapid; R103757 |
CAS Number | 179602-65-4 |
PubChem (CID) | 213047 |
ChemSpider | 184740 |
UNII | FVW7T75XP4 |
KEGG | D05060 |
Chemical and physical data | |
Formula | C36H41ClN8O4S |
Molar mass | 717.28 g/mol |
3D model (Jmol) | Interactive image |
| |
|
Mitratapide is a veterinary drug for the treatment of overweight and obese dogs sold under the brand name Yarvitan. Its mechanism of action involves inhibition of microsomal triglyceride transfer protein (MTP) which is responsible for the absorption of dietary lipids.[3] Clinical study also suggests that mitratapide may help to reverse insulin resistance in dogs.[4]
The drug was developed by Janssen Pharmaceutica and is chemically related to the antifungal drugs such as itraconazole which were also developed by Janssen.
See also
References
- ↑ "Yarvitan 5 mg/ml Oral Solution for Dogs. Summary of Product Characteristics" (PDF). www.ema.europa.eu. Retrieved 27 August 2016.
- ↑ "Yarvitan (mitratapide). Scientific Discussion" (PDF). www.ema.europa.eu. Retrieved 27 August 2016.
- ↑ Mitratapide, vetstream.com
- ↑ Dobenecker, B; De Bock, M; Engelen, M; Goossens, L; Scholz, A; Kienzle, E (2009). "Effect of mitratapide on body composition, body measurements and glucose tolerance in obese Beagles". Veterinary research communications. 33 (8): 839–47. doi:10.1007/s11259-009-9232-5. PMC 2776940. PMID 19544001.
This article is issued from Wikipedia - version of the 8/27/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.